Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
Trial details
- Registry ID
- NCT04006119
- Phase
- Phase 2
The FDA approved Cemiplimab-Rwlc (Libtayo) on 28 Sep 2018.
Drug identity checked against registry records
Also recorded as Libtayo; REGN2810
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive GlioblastomaNCT04006119 | Alaunos Therapeutics | Phase 2 | Terminated | 2021-08-05Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2018-09-28Day | Cemiplimab-Rwlc | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761097", "applicant_as_listed_by_fda": "REGENERON PHARMACEUTICALS", "brand_names": ["LIBTAYO"], "active_ingredients": ["CEMIPLIMAB-RWLC"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20180928", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |